News + Font Resize -

Sicor reacquires mktg rights to aaiPharma's calcitriol
Wilmington, North Carolina | Tuesday, December 28, 2004, 08:00 Hrs  [IST]

aaiPharma Inc announced that SICOR Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., has reacquired its US marketing rights for calcitriol injection in exchange for certain payments to aaiPharma.

Calcitriol injection vial is a drug used primarily to treat chronic kidney dialysis patients with abnormally low levels of calcium in their blood.

Dr. Ludo J. Reynders, president and CEO of aaiPharma said, "This transaction represents a small but important step in our initiative to rationalize and simplify our business."

aaiPharma Inc. is a science-based pharmaceutical company focused on pain management, with corporate headquarters in Wilmington, North Carolina.

Post Your Comment

 

Enquiry Form